MG-132_133407-82-6_MSDS_MedChemExpress
HSF1A_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:HSF1A is a cell–permeable activator of heat shock transcription factor 1 (HSF1).IC50 & Target: HSF1[1]In Vitro: HSF1A protects cells from stress–induced apoptosis, binds TRiC subunits and inhibits TRiC activity without perturbation of ATP hydrolysis. Genetic inactivation or depletion of the TRiC complex results in human HSF1 activation and HSF1A inhibits the direct interaction between purified TRiC and HSF1 in vitro. Moreover, fluorescence anisotropy experiments using FITC coupled to HSF1A demonstrates that HSF1A–FITC binds to a purified Tcp1 subunit of TRiC with an affinity of approximately 600 nM. This is validated qualitatively via titration of purified Tcp1 into binding reactions containing 500 nM Biotin or HSF1A–Biotin [1]. Quantification bycounting the number of cell containing aggregates as a function of the total number of cells reveals that at HSF1A concentrations as low as 2 μM, a reduced number of aggregate–containing cells are observed. The fraction of cells containing aggregates continued to decrease in a dose–dependent manner such that pretreatment with 12 μM HSF1A resulta in ~20% of the cells exhibiting aggregates visible by fluorescence microscopy [2].In Vivo: HSF1A enhances HSF1 activity, stabilizes HSF1 expression and minimizes Doxorubicin (DOX)–induced cardiac damage. WKY rats are challenged with DOX (accumulated dose: 30 mg/kgw), and DOX combined with HSF1A (100 mg/kgw/day). Supplementation with HSF1A significantly elevates cardiac functions back to the levels of the control group. HSF1A has been shown to stimulate human HSF1 nuclear translocation, elevate protein chaperone expression and ameliorate protein misfolding and cell death in aneurodegenerative disease model. The echocardiographic results show that HSF1A also alleviates DOX–induced failures in cardiac function [3].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]Protein extracts are generated from mammalian, yeast and E. coli cultures using biotin–binding buffer (20 mM HEPES,5 mM MgCl 2, 1 mM EDTA, 100 mM KCl, 0.03% NP–40) supplemented with 1% Trition–X100 and protease inhibitors. Approximately 0.5mg of protein extract is incubated with 100 μM HSF1A–Biotin for 4 h at 4°C and HSF1A–Biotin associated proteins captured by with NeutrAvidin Agarose Resin. After washing in biotin binding buffer proteins are eluted using 50 μL biotin elution buffer (100 mM Tris,150 mM NaCl, 0.1 mM EDTA, 2 mM D–biotin), resolved on a 4–20% SDS–PAGE, and immunoblotted. For purified TRiC and Hsp70analyses, 5 nM protein is incubated in biotin–binding buffer+0.5% Triton X–100 with 100 μM biotin or 100 μM HSF1A–Biotin for 4 h at 4°C and captured with NeutrAvidin Resin. For NiNTA purified yeast Tcp1, different concentrations of Tcp1 0.5 μM, 1 mM, 2 mM, 3 mM and 4 mM in 25 mM Hepes pH 7.5, 150 mM NaCl are incubated with 0.5 μM Biotin or HSF1A–Biotin for 4 h at 4°C and captured with NeutrAvidin Resin [1].Cell Assay:[2]PC12 cells seeded into a 96–well plate (5×104 cells/well) are treated with increasing concentrations of HSF1A (2, 4, 8 andProduct Name:HSF1A Cat. No.:HY-103000CAS No.:1196723-93-9Molecular Formula:C21H19N3O2S2Molecular Weight:409.52Target:HSP Pathway:Cell Cycle/DNA Damage; Metabolic Enzyme/Protease Solubility:DMSO: ≥ 150 mg/mL12 μM) for 15 h, at which time httQ74–GFP expression is stimulated by incubation in the presence of 1 μg/mL Doxycycline for 5 d. Cell viability is assessed via the XTT viability assay[2].Animal Administration:[3]Rat[3]Ten–week–old Wistar Kyoto rats (WKY) are used. The rats are housed at a constant temperature (22°C) on a 12–h light/dark cycle with food and tap water. The animals are arranged into three groups: WKY rats (the control group), DOX rats and DOX rats treated with HSF1A. Each group contain five animals. The DOX group is injected with DOX (5 mg/kg) for 6 consecutive weeks intraperitoneal injection to achieve a cumulative dose of 30 mg/kg, which has been well documented to achieve cardiotoxicity. The small molecular HSF1 activator HSF1A (100 mg/kg/day) is injected intraperitoneally.References:[1]. Neef DW, et al. A direct regulatory interaction between chaperonin TRiC and stress–responsive transcription factor HSF1. Cell Rep. 2014 Nov 6;9(3):955–66.[2]. Neef DW, et al. Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease. PLoS Biol. 2010 Jan 19;8(1):e1000291.[3]. Huang CY, et al. Doxorubicin attenuates CHIP–guarded HSF1 nuclear translocation and protein stability to trigger IGF–IIR–dependent cardiomyocyte death. Cell Death Dis. 2016 Nov 3;7(11):e2455.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
危险化学品安全技术说明书及周知卡
危险化学品安全技术说明书及相关安全周知卡目录1、乙酸2、盐酸3、乙醇4、甲醇5、甲苯6、纯苯7、液氨8、三乙胺9、甲醛10、氯乙醛11、氯化亚砜12、二甲基甲酰胺13、水杨醛14、氢氧化钠15、碳酸钠16、碳酸钾17、三氯化铝18、乙酸酐19、对甲苯磺酰氯20、对甲氧基苯甲酸21、碘22、焦亚硫酸钠23、乙酸钠24、双氧水非常全面，给需要的同行参考。
危险化学品安全信息卡空气呼吸器。
眼睛防护：戴化学安全防护眼镜。
身体防护：穿防酸碱塑料工作服。
手防护：戴橡胶耐酸碱手套。
其他防护：工作现场严禁吸烟。
工作完毕，淋浴更衣。
注意个人清洁卫生。
急救措施皮肤接触：立即脱去污染的衣着，用大量流动清水冲洗至少15分钟。
就医。
眼睛接触：立即提起眼睑，用大量流动清水或生理盐水彻底冲洗至少15分钟。
就医。
吸入：迅速脱离现场至空气新鲜处。
保持呼吸道通畅。
如呼吸困难，给输氧。
如呼吸停止，立即进行人工呼吸。
就医。
食入：用水漱口，就医。
泄漏处理迅速撤离泄漏污染区人员至安全区，并进行隔离，严格限制出入。
切断火源。
建议应急处理人员戴自给正压式呼吸器，穿防酸碱工作服。
不要直接接触泄漏物。
尽可能切断泄漏源。
防止流入下水道、排洪沟等限制性空间。
小量泄漏：用砂土、干燥石灰或苏打灰混合。
大量泄漏：构筑围堤或挖坑收容。
喷雾状水冷却和稀释蒸汽、保护现场人员、把泄漏物稀释成不燃物。
用防爆泵转移至槽车或专用收集器内，回收或运至废物处理场所处置。
消防措施有害燃烧产物：一氧化碳、二氧化碳。
灭火方法：用水喷射逸出液体，使其稀释成不燃性混合物，并用雾状水保护消防人员。
灭火剂：雾状水、抗溶性泡沫、干粉、二氧化碳。
危险化学品安全周知卡危险性类别腐蚀品刺激性品名、英文名及分子式、CC码及CAS号醋酸（冰醋酸，乙酸）Acetic acid危险性标志危险性理化数据熔点（℃）：沸点（℃）：危险特性其蒸气与空气形成爆炸混合物，遇明火、高热能引起爆炸。
与强氧化剂可发生反应，与现场急救措施皮肤接触：脱去所污染的衣服，用流动清水冲洗至少15分钟；若有灼伤，就医治疗。
氨苄青霉素麦康凯配套试剂产品说明书
化学品安全技术说明书第一部分化学品及企业标识产品中文名称：氨苄青霉素麦康凯配套试剂产品英文名称：Additives for Ampicillin Macconkey Agar产品编号：SR0520企业名称：广东环凯微生物科技有限公司地址：广东省广州市黄埔区广州开发区科学城神舟路788号邮编：510663公司网址电子邮件地址：*********************传真号码：************销售热线：************-8602技术热线：************-8877/8876推荐用途和限制用途：生化研究/分析第二部分危险性概述GSH危害性类别非危险物质或混合物GSH标签要素无数据资料其它危害（健康危害、环境危害）未见报道第三部分成分/组成信息混合物化学品成分：参考产品说明。
有害物质成分：无第四部分急救措施一般信息：无特殊的措施要求。
皮肤接触：立即用清水彻底清洗。
眼睛接触：立即提起眼睑，用大量流动清水冲洗15min。
如不适就医。
吸入：如果吸入，将人员移动到新鲜空气处，如果没有呼吸，进行人工呼吸操作，并联系医生。
食入：如误食，用水冲洗口腔，如不适就医。
就医信息：出示产品使用说明或者此SDS。
第六部分 泄露应急处理个人防护： 穿个人实验服,佩戴手套和口罩,。
环境保护措施： 用湿布和地拖擦拭干净。
清洁/收集措施： 保持干燥。
迅速清洗弄脏的区域。
第七部分 操作处置与储存安全操作注意事项： 应提供通风设备。
储存注意事项： 贮存于2-8℃避光、干燥处。
第八部分 接触控制/个人防护职业接触限值 没有已知的国家规定的暴露极限。
工程控制： 提供安全淋浴和洗眼设备个人保护措施 呼吸系统防护： 在通风橱里称取产品，佩戴口罩。
眼睛防护： 佩戴安全眼镜。
身体防护： 穿实验室服。
手防护： 戴防化学品手套。
其他防护： 常规的工业卫生操作，工作后及时清洗双手。
第九部分 理化特性外观： 固体 pH 值： 无数据资料 颜色： 白色 气味： 特征性 熔点： 无数据资料 沸点： 无数据资料 燃点： 无数据资料闪点：无数据资料爆炸限度 下限： 无数据资料 上限： 无数据资料 热分解：无数据资料溶解性：易溶于水第五部分 消防措施危险特性： 不助燃。
美国Medchemexpress化合物库(小分子库)_Medchemexpress_(MCE中国)
美国Medchemexpress化合物库（小分子库）-原装进口，现货供
应，提供组合定制服务
品牌：Medchemexpress （MCE）
保存条件：-20℃
供应商：MCE中国
数量：大量
保质期：2年
Size：
Pre-dissolved DMSO/Solid（Or dry solid）
100 uL/well (10 mM solution)
200 uL/well (10 mM solution)
MedChemExpress (MCE)专注于各种抑制剂、调节剂、API、天然产物及化合物库，总部位于美国新泽西。
MCE经过十年努力已成为全球生物活性小分子领域的一流供应商。
MedChemExpress(MCE)产品涵盖近20个热门研究领域，1000多个细分靶点，超过3000个现货抑制剂、拮抗剂和激动剂。
相关的应用成果已发表于Nature、Cell等国际知名杂志，在全球20余个国家地区设有代理机构。
上海皓元生物医药科技有限公司(MCE 中国) 是MedChemExpress (MCE) 亚洲总代理。
MCE化合物库涵盖20余种不同的类型，超过2500个化合物，进口原装，
现货供应，提供详实的生物活性信息、化学结构信息、质控图谱（NMR和HPLC 等）。
还可根据您的实际研究需要，为您度身定制任意组合、规格、布板的特殊化合物库。
/screening-libraries.html
现有特色化合物库有：。
德国美剂乐药用乳糖
700
710
[g/l]
660
790
820
1.1
1.13
1.15
1313
InhaLac® 70
粒度分布(激光衍射)
InhaLac® 70
密度分布 (%)
累积分布 (%)
100
90
80
70
60
50
40
30
20
10
0
0
10
100
粒径 (µm)
500 µm
20 18 16 14 12 10 8 6 4 2 0 1000
药用乳糖
应用于直接压片、制粒、胶囊填充、颗粒剂填充、 丸芯、粉末混合和干粉吸入剂等固体制剂生产的 药用辅料
MEGGLE Excipients & Technology
2
据我们的知识所及，本资料中所有 信息均是正确的。但对本资料中的 所有内容不作任何法律上的担保
MEGGLE Group Wasserburg BG Excipients & Technology 地址： Megglestraße 6 –12
500 µm
1100
筛分乳糖
SacheLac® 80
应用范围 － 胶囊填充 － 颗粒剂填充 － 粉末混合 － 研磨工艺
典型柱形图 SacheLac® 80 质量 (%) 100 90 80 70 60 50 40 30 20 10
0 0 100 200 300 400 500 粒径 (µm)
500 µm
/ 75 % ≥ 90 %/ 97.5 %
≥ 90 %/ 96 %
/ 99.5 %
40 – 60 %/ 50 % ≥ 80 %/ 90 % ≥ 90 %/ 98.4 %
阿司咪唑
合成方法
合成方法
化合物(I)和碘甲烷在乙醇中回流8h，环合得到化合物(Ⅱ)。再水解脱去酯基，得到化合物(Ⅲ)。用对甲氧 基苯乙基溴进行N-烷基化，得化合物(Ⅳ)。再用对氟苄基溴烷基化，得阿司咪唑。
1. 1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮的制备
在反应瓶中加入2-羟基苯并咪唑5.0g(37.3mmol)和NaH 1.6g(53mmol)(NaH含量大约为80%,浸入矿物油中) 的DMF 100ml的悬浮液.加毕.在60ºC.(最好有N2保护)搅拌反应1h.再加入4-氟苄基氯(FBC)5.4g(37mmol),加热 ( 6 0 ºC ) 搅 拌 反 应 5 . 5 h . 冷 却 至 室 温 后 加 入 冰 水 7 0 0 m l , 用 二 氯 甲 烷 ( 5 0 0 m l × 2 ) 提 取 . 有 机 层 用 食 盐 水 洗 . 无 水 N a 2 S O 4 干燥.过滤.滤液减压浓缩.剩余物用石油醚析晶.得1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮固体8.0g,为无色 结 晶 m p 1 7 8 ~ 1 7 9 ºC , 收 率 8 8 % .
治疗措施
阿司咪唑中毒的治疗要点为： 1.大量摄入者予洗胃，后灌服活性炭和导泻。 2.对心肌抑制和Q-T间期延长者予5%碳酸氢钠250ml静注可能有效。 3.对症、支持治疗。
专家点评
专家点评
阿司咪阿司咪唑自1983年上市以来，在许多国家得到了广泛应用。国外研究显示阿司咪唑治疗荨麻疹的总有 效率为74%。国内的一项多中心双盲安慰剂对照试验表明阿司咪唑对急性荨麻疹的总有效率为82.9%，对慢性荨麻 疹的总有效率为86.0%，均显著高于安慰剂，主要不良反应为嗜睡、倦怠、口干等，连续用药3个月的患者中，半 数有食欲及体重增加。阿司咪唑的心脏毒性虽然发生率较低，但由于后果严重，已限制了它的应用。阿司咪唑为 强效和长效的H1受体拮抗剂，无中枢镇静和抗毒蕈碱样作用。代谢产物去甲阿司咪唑仍有抗胆胺作用。长期服用 可增进食欲和增加体重，服用过量可引起心脏Q-T间期延长和室性心律失常。适用于各种原因引起过敏性疾病。
Medlife,81-27-6,番泻苷 A,技术规格说明书(SDS)
81-27-6|番泻苷 A，技术规格说明书(SDS)简介：番泻苷 A，Sennoside A 是一种蒽醌苷，在番泻叶 (Cassia angustifolia) 的叶子和豆荚中大量发现。
Sennoside A 是一种 HIV-1 抑制剂，抑制 HIV-1 复制。
番泻苷 A物理化学性质：番泻苷 A详细介绍：番泻苷 A;番泻草苷A;番泻叶苷A;番泻苷A 番泻叶苷A;WAKO197-13931番泻苷A;zzstandard 品牌番泻苷A对照品;番茄汁;番泻草苷;番泻甙A标准品(JP);番泻苷 A Sennoside A;番泻苷 A标准品;番泻苷AUSP标准品;番泻苷A（标准品）;番泻苷A(番泻草苷A);番泻苷A,Sennoside A,植物提取物,标准品,对照品;番泻苷一;番泻提取物;番泻叶甙 A(AS);番泻叶甙 A(P);番泻叶苷;纳米级番泻叶提取物;番泻苷A;番泻叶甙A;分析对照品;环氧(5Z,8Z,14Z)-11,14,17-二十碳三烯酸;桑白皮提取物10:1;番泻苷A番泻苷 A参考文献：[1]. Rama Reddy NR, et al. Next Generation Sequencing and Transcriptome Analysis Predicts Biosynthetic Pathway of Sennosides from Senna (Cassia angustifolia Vahl.), a Non-Model Plant with Potent Laxative Properties. PLoS One. 2015 Jun 22;10(6):e0129422.[2]. Esposito F, et al. Sennoside A, derived from the traditional chinese medicine plant Rheum L., is a new dual HIV-1 inhibitor effective on HIV-1 replication. Phytomedicine. 2016 Nov 15;23(12):1383-1391.产品技术规格说明书由上海创赛科技有限公司收集整理，仅作参考使用。
危险化学品安全技术说明书及周知卡
危险化学品安全技术说明书及相关安全周知卡目录1、乙酸2、盐酸3、乙醇4、甲醇5、甲苯6、纯苯7、液氨8、三乙胺9、甲醛10、氯乙醛11、氯化亚砜12、二甲基甲酰胺13、水杨醛14、氢氧化钠15、碳酸钠16、碳酸钾17、三氯化铝18、乙酸酐19、对甲苯磺酰氯20、对甲氧基苯甲酸21、碘22、焦亚硫酸钠23、乙酸钠24、双氧水非常全面，给需要的同行参考。
危险化学品安全信息卡空气呼吸器。
眼睛防护：戴化学安全防护眼镜。
身体防护：穿防酸碱塑料工作服。
手防护：戴橡胶耐酸碱手套。
其他防护：工作现场严禁吸烟。
工作完毕，淋浴更衣。
注意个人清洁卫生。
急救措施皮肤接触：立即脱去污染的衣着，用大量流动清水冲洗至少15分钟。
就医。
眼睛接触：立即提起眼睑，用大量流动清水或生理盐水彻底冲洗至少15分钟。
就医。
吸入：迅速脱离现场至空气新鲜处。
保持呼吸道通畅。
如呼吸困难，给输氧。
如呼吸停止，立即进行人工呼吸。
就医。
食入：用水漱口，就医。
泄漏处理迅速撤离泄漏污染区人员至安全区，并进行隔离，严格限制出入。
切断火源。
建议应急处理人员戴自给正压式呼吸器，穿防酸碱工作服。
不要直接接触泄漏物。
尽可能切断泄漏源。
防止流入下水道、排洪沟等限制性空间。
小量泄漏：用砂土、干燥石灰或苏打灰混合。
大量泄漏：构筑围堤或挖坑收容。
喷雾状水冷却和稀释蒸汽、保护现场人员、把泄漏物稀释成不燃物。
用防爆泵转移至槽车或专用收集器内，回收或运至废物处理场所处置。
消防措施有害燃烧产物：一氧化碳、二氧化碳。
灭火方法：用水喷射逸出液体，使其稀释成不燃性混合物，并用雾状水保护消防人员。
灭火剂：雾状水、抗溶性泡沫、干粉、二氧化碳。
危险化学品安全周知卡危险性类别腐蚀品刺激性品名、英文名及分子式、CC码及CAS号醋酸（冰醋酸，乙酸）Acetic acid危险性标志危险性理化数据熔点（℃）：沸点（℃）：危险特性其蒸气与空气形成爆炸混合物，遇明火、高热能引起爆炸。
与强氧化剂可发生反应，与现场急救措施皮肤接触：脱去所污染的衣服，用流动清水冲洗至少15分钟；若有灼伤，就医治疗。
MG-132_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :MG-132Catalog No. :HY-13259CAS No. :133407-82-61.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:MG132; MG 132Formula:C26H41N3O5Molecular Weight:475.62CAS No. :133407-82-64. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
6066-82-6_MedBio_N-Hydroxysuccinimide分子量
95-98 °C(lit.)
闪点
112.5±22.6 °C
2、同类产品列表：
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11052
芴甲氧羰基-L-天冬氨酸-1-叔丁酯
Fmoc-Asp-OtBu
129460-09-9
25g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11112
Fmoc-Ser(HPO3Bzl)-OH
158171-14-3
10g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11128
Fmoc-丝氨酸磷酸苄酯
Fmoc-Ser(HPO3Bzl)-OH
158171-14-3
50g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11097
MED11058
D-2,4-二氨基丁酸二盐酸盐
H-D-Dab-OH.2HCl
127531-11-7
1g
≥98%
6066-82-6_MedBio_N-Hydroxysuccinimide
1、产品物理参数：
常用名
N-羟基琥珀酰亚胺
英文名
N-Hydroxysuccinimide
CAS号
6066-82-6
分子量
115.087
密度
1.6±0.1 g/cm3
沸点
262.4±23.0 °C at 760 mmHg
注射用三磷酸腺苷二钠氯化镁
本品为复方制剂，其组份为：三磷酸腺苷二钠0.1g与氯化镁32mg。
化学名称：三磷酸腺苷二钠及氯化镁。
三磷酸腺苷二钠的化学名称：腺嘌呤核苷-5’-三磷酸酯二
本品为辅助用药，用于急性、慢性活动型肝炎、缺血性脑血管病后遗症、脑损伤、
静脉滴注：溶于5%葡萄糖注射液250-500ml中，混匀。
初始滴速操纵在每分钟20滴之内，如无异样5分钟后，操纵在每分钟50滴之内。
一日一次，一次用量5mg/Kg。
静脉滴速过快有降压作用，可引发胸闷、全身灼热感，停药或减慢滴速可恢复正常
本品为高能复合物，可透过各重要脏器的细胞膜，增加组织和细胞内ATP水平。
在缺血缺氧状态下给细胞直接供能，从而改善细胞能量、代谢及细胞膜钠泵机制，减轻细胞肿胀，改善微循环障碍，恢复脏器功能。
本品能改善休克所致的大鼠肝细胞膜通透性，有效恢复缺血性肝细胞功能，本品能改善细胞能量代谢、改善微循环障碍、改善巨噬细胞功能。
本品能够进入缺血缺氧的心肌细胞线粒体，支持细胞功能，改善细胞内外的钠、钾、镁平稳失调，抑制细胞内Ca2+聚集。
本品有必然清除氧自。
美国药典USP-1478549奥美拉唑镁的msds
Material Safety Data Sheet USP Reference Standards are sold for chemical test and assay purposes only, and NOT for human consumption. The information contained herein is applicable solely to the chemical substance when used as a USP Reference Standard and does not necessarily relate to any other use of the substance described, (i.e. at different concentrations, in drug dosage forms, or in bulk quantities). USP Reference Standards are intended for use by persons having technical skill and at their own discretion and risk. This information has been developed by USP staff from sources considered reliable but has not beenindependently verified by the USP. Therefore, the USP Convention cannot guarantee the accuracy of the information in these sources nor should the statements contained herein be considered an official expression. NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE is made with respect to the information contained herein.ATTENTION !12601 Twinbrook Parkway, Rockville, MD 20852 USA Phone Calls:301-816-81298 a.m. to 5 p.m. EST Mon. - Fri.OMEPRAZOLE MAGNESIUM Catalog Number:1478549Revision Date:March 20, 2007SECTION 2 - HAZARD INFORMATIONCommon Name:Omeprazole Magnesium SECTION 1 - PRODUCT AND COMPANY IDENTIFICATIONSECTION 3 - COMPOSITION/INFORMATION ON INGREDIENTSEMERGENCY OVERVIEW - Allergen.Adverse Effects:Adverse effects of omeprazole may include cough; nasal or ear congestion; chills, fever, or sore throat; loss of voice;runny nose; difficulty breathing; body aches or pains; heart burn, diarrhea, gas, skin rash or itching, unusual tiredness,dizziness, constipation, headache, and nausea or vomiting. Possible allergic reaction to material if inhaled, ingestedor in contact with skin.Overdose Effects:Symptoms of omeprazole overdose may include blurred vision, confusion, increased sweating, drowsiness, drymouth, flushing, headache, severe stomach pain, nausea or vomiting, and fast or irregular heartbeat.Acute:Possible eye, skin, gastrointestinal and/or respiratory tract irritation.Chronic:Possible hypersensitization.Medical Conditions Aggravated by Exposure:Hypersensitivity to the material and chronic liver disease (current or history of).Cross Sensitivity:n/fTarget Organs:Gastrointestinal tractFor additional information on toxicity, see Section 11.Common Name:Omeprazole MagnesiumFormula:C34H36MgN6O6S2Manufacturer:U. S. PharmacopeiaResponsible Party:Reference Standards Technical ServicesMailing Address:12601 Twinbrook Parkway, Rockville, MD 20852 USAPhone:301-816-8129Hours:8 a.m. to 5 p.m. EST Mon. - Fri.Product Use:USP Reference Standards and Authentic Substances are used for chemical tests and assays in analytical,clinical, pharmaceutical, and research laboratories.Synonym:n/fChemical Name:5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, magnesium salt (2:1) CAS:95382-33-5RTECS Number:n/fChemical Family:Substituted benzimidazoleTherapeutic Category:Gastric acid secretory depressantComposition:Pure MaterialSECTION 4 - FIRST AID MEASURESInhalation:May cause irritation. Avoid inhalation. Remove to fresh air.Eye:May cause irritation. Avoid contact. Flush with copious quantities of water for at least 15 minutes.Skin:May cause irritation and sensitization. Avoid contact. Flush with copious quantities of soap and water.Ingestion:May cause irritation. Flush out mouth with water.General First Aid Procedures:Remove from exposure. Remove contaminated clothing. Persons developing serious hypersensitivity(anaphylactic) reactions must receive immediate medical attention. If person is not breathing giveartificial respiration. If breathing is difficult give oxygen. Obtain medical attention.Note to PhysiciansOverdose Treatment:Treatment of omeprazole overdose should be symptomatic and supportive and may include the following:1. Administer activated charcoal as a slurry.2. Sinus tachydysrhythmias do not need to be routinely treated unless patient is hemodynamically unstable.3. Omeprazole is not readily dialyzable. [Meditext 2007 & USP DI 2007]SECTION 5 - FIREFIGHTING MEASURESExtinguisher Media:Water spray, dry chemical, carbon dioxide or foam as appropriate for surrounding fire and materials.Fire and Explosion Hazards:This material is assumed to be combustible. As with all dry powders it is advisable to ground mechanical equipment in contact with dry material to dissipate the potential buildup of static electricity.Firefighting Procedures:As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathingequipment and protective clothing.SECTION 6 - ACCIDENTAL RELEASE MEASURESSpill Response:Wear approved respiratory protection, chemically compatible gloves and protective clothing. Wipe up spillage or collect spillage using a high efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labeledcontainer for disposal. Wash spill site.SECTION 7 - HANDLING AND STORAGEHandling:As a general rule, when handling USP Reference Standards avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Wash thoroughly after handling.Storage:Store in tight, light-resistant container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity. Store in a refrigerator.SECTION 8 - EXPOSURE CONTROL / PERSONAL PROTECTIONEngineering Controls:Engineering controls such as exhaust ventilation are recommended.Respiratory Protection:Use a NIOSH-approved respirator, if it is determined to be necessary by an industrial hygiene surveyinvolving air monitoring. In the event that a respirator is not required, an approved dust mask should be used. Gloves:Chemically compatibleEye Protection:Safety glasses or gogglesProtective Clothing:Protect exposed skin.Exposure Limits:Industry: 0.5 mg/m3 (omeprazole)SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIESProperties as indicated on the MSDS are general and not necessarily specific to the USP Reference Standard Lot provided. Appearance and Odor:White to almost white crystalline powderOdor Threshold:n/fpH:Approximately 10.5 (aqueous suspension)Melting Range:n/fBoiling Point:n/fFlash Point:n/fAutoignition Temperature:n/fEvaporation Rate:n/fUpper Flammability Limit:n/fLower Flammability Limit:n/fVapor Pressure:n/fVapor Density:n/fSpecific Gravity:n/fSolubility in Water:Very slightly solubleFat Solubility:n/fOther Solubility:Soluble in methanolPartition Coefficient: n-octanol/water:n/fPercent Volatile:n/fReactivity in Water:n/fExplosive Properties:n/fOxidizing Properties:n/fFormula:C34H36MgN6O6S2Molecular Weight:713.12Oral Rat:LD50: >2000 mg/kgOral Mouse:n/fNTP:No IARC:No OSHA:NoListed as a Carcinogen by: Irritancy Data:n/f SECTION 11 - TOXICOLOGICAL PROPERTIESOther Toxicity Data:n/fCorrosivity:n/f Sensitization Data:Omeprazole is a strong sensitizer in guinea pigs. (Guinea pig maximization test)Other Carcinogenicity Data:No evidence of carcinogenicity was found in mice orally administered up to 140 mg/kg/day omeprazolefor 66 weeks. In two 2-year studies in rats, omeprazole given in doses up to 140.8 mg/kg/day causedgastric carcinoid tumors and enterochromaffin-like (ECL) cell hyperplasia in a dose-dependent manner in both males and females.Mutagenicity Data:Omeprazole produced clastogenic effects in an in vitro human lymphocyte chromosomal aberration assay, in oneof two in vivo mouse micronucleus tests, and in an in vivo bone marrow cell chromosomal aberration assay. Omeprazole was negative in the in vitro Ames Salmonella typhimurium assay, an in vitro mouse lymphoma cell forward mutation assay, and an in vivo rat liver DNA damage assay.Reproductive and Developmental Effects:Sporadic instances of developmental abnormalities in infants born to women who receivedomeprazole during pregnancy have been reported. Epidemiological studies have not foundan association between the use of omeprazole during pregnancy and an increased risk ofbirth defects.Omeprazole did not impair fertility in rats at parenteral doses of up to 138 mg/kg/day. Nobirth defects were seen in pregnant rabbits and rats administered omeprazole in doses up to69 mg/kg/day and 138 mg/kg/day, respectively.In rabbits, 6.9 - 69.1 mg/kg/day omeprazole produced dose-related increases in embryo-lethality, fetal resorptions, and pregnancy disruption. In rats, dose-related embryo/fetaltoxicity and post natal developmental toxicity were observed in the rat offspring of parentstreated with 13.8 - 138 mg/kg/day.SECTION 12 - ECOLOGICAL INFORMATIONEcological Information:Omeprazole sodium, a related compound, may cause long-term adverse effects in the aquatic environment andis not readily biodegradable.SECTION 13 - DISPOSAL CONSIDERATIONSDisposal:Dispose of waste in accordance with all applicable Federal, State and local laws.SECTION 14 -TRANSPORT INFORMATIONShipping Name:n/fClass:n/f Stable?Yes Conditions to Avoid:Avoid exposure to light.Incompatibilities:n/fDecomposition Products:When heated to decomposition material emits toxic fumes of SOx and NOx. Emits toxic fumes under fireconditions.Hazardous Polymerization?No SECTION 10 - STABILITY AND REACTIVITYUN Number:n/fPacking Group:n/fAdditional Transport Information:n/fSECTION 15 - REGULATORY INFORMATION U.S. Regulatory Information:n/fInternational Regulatory Information:Risk Phrases: R43, R52/53Safety Phrases: S37, S61SECTION 16 - OTHER INFORMATIONRevision:20-Mar-07Previous Revision Date:05-Feb-07。
多格列艾汀化学结构式
多格列艾汀化学结构式
多格列艾汀是一种化学结构式，它是一种抗癫痫药物，用于控制癫痫发作。
它的化学名是（S）-N-（2,6-二甲基苯基）-1,2,3,4-四氢-6,7-二氧-1-哌啶甲酰胺。
多格列艾汀的分子式为C16H21N3O2，分子量为287.36。
多格列艾汀的结构式如下：
这是一个由苯环、哌啶环和氨基甲酸酯基团组成的分子。
苯环是由6个碳原子和6个氢原子组成的芳香环，哌啶环是由6个碳原子、1个氮原子和3个氢原子组成的非芳香环。
氨基甲酸酯基团由一个氨基（NH2）和一个甲酸酯基（C(O)OCH3）组成。
多格列艾汀通过作用于中枢神经系统，调节神经元的兴奋性，从而减少癫痫发作的次数和强度。
它主要通过抑制神经元的电气活动来发挥作用。
多格列艾汀被认为是一种选择性的钠通道阻滞剂，它能够减少神经元的电流传导，从而减少癫痫发作的可能性。
多格列艾汀是一种处方药物，需要在医生的指导下使用。
在使用多格列艾汀之前，应该充分了解其副作用和注意事项。
常见的副作用包括头痛、头晕、嗜睡、精神症状等。
在使用多格列艾汀期间，应定期进行血液检查，以监测药物的疗效和安全性。
多格列艾汀是一种用于控制癫痫发作的药物，它通过调节神经元的兴奋性来发挥作用。
然而，使用多格列艾汀需要在医生的指导下进
行，并且需要注意其副作用和注意事项。
希望本文对读者对多格列艾汀有更深入的了解和认识。
砷酸镁安全技术说明书MSDS
第一部分化学品及企业标识化学品中文名：砷酸镁化学品英文名：magnesium arsenateCASNo.：10103-50-1ECNo.：233-285-7分子式：AsH3O4·xMg第二部分危险性概述紧急情况概述固体。
吞食后有毒。
吸入有毒。
对水生物有剧毒,使用适当的容器,以预防污染环境。
对水生环境可能会引起长期有害作用。
使用适当的容器,以预防污染环境。
GHS危险性类别根据GB30000-2013化学品分类和标签规范系列标准（参阅第十六部分），该产品分类如下：急毒性-口服，类别3；急毒性-吸入，类别3；致癌性，类别1A；危害水生环境-急性毒性，类别1；危害水生环境-慢性毒性，类别1。
标签要素象形图警示词：危险危险信息：吞咽会中毒，吸入会中毒，可能致癌，对水生生物毒性极大，对水生生物毒性极大并具有长期持续影响。
预防措施：使用前取得专业说明。
在阅读并明了所有安全措施前切勿搬动。
避免吸入粉尘/烟/气体/烟雾/蒸气/喷雾。
作业后彻底清洗。
使用本产品时不要进食、饮水或吸烟。
只能在室外或通风良好之处使用。
避免释放到环境中。
戴防护手套/穿防护服/戴防护眼罩/戴防护面具。
事故响应：呼叫中毒急救中心/医生。
漱口。
收集溢出物。
如误吞咽：立即呼叫中毒急救中心/医生。
如误吸入：将受人转移到空气新鲜处，保持呼吸舒适的体位。
如接触到或有疑虑：求医/就诊。
安全储存：存放处须加锁。
存放在通风良好的地方。
保持容器密闭。
废弃处置：按照地方/区域/国家/国际规章处置内装物/容器。
物理化学危险：无资料健康危害：吸入本品在正常生产过程中生成的粉尘可对身体产生毒害作用。
吸入该物质可能会引起对健康有害的影响或呼吸道不适。
意外食入本品可能引起毒害作用。
意外食入本品可能对个体健康有害。
通过割伤、擦伤或病变处进入血液，可能产生全身损伤的有害作用。
眼睛直接接触本品可导致暂时不适。
环境危害：本品对水生生物毒性极大。
本品对水生生物毒性极大并具有长期持续影响。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
MSDS
1 Composition
7 Accident Release Measure
Product Name:MG-132
Chemical Name:
PROCEDURE(S) OF PERSONAL PRECAUTION(S)-Wear respirator, chemical safety goggles, rubber boots, and heavy rubber gloves.
METHODS FOR CLEANING UP-Sweep up, place in a bag and hold for waste disposal. Avoid raising dust. Ventilate area and
wash spill site after material pickup is complete.
L-Leucinamide, N-[(phenylmethoxy)carbonyl]-L-leucyl-N-[(1S)-1-formyl-3-methylbutyl]-
CAS No.:133407-82-6
8 Accident Release Measure
Appearance:White to off-white(solid)Formula:C26H41N3O5
9 Toxicological Information
Solubility:
To the best of our knowledge, the chemical, physical, and
toxicological properties have not been thoroughly investigated.
No data available.
p p p p DMSO ı90mg/mL Water <1.2mg/mL
Ethanol ı90mg/mL
2 Handling and Storage
10 Regulary Information
3 Stability and Reactivity
Disposal CLASSIFICATION- Substance not yet fully tested.
SAFETY PHASES- 26-36 (In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing.) 36/37/38 (Irritating to eyes,respiratory system and skin.)
STABILITY- Stable under normal handling conditions.HANDLING- Do not breathe dust. Avoid contact with eyes,skin,and clothing.Avoid prolonged or repeated exposure.
STORAGE- Store in a properly sealed container store at -20ć,shelflife is 2 years.
11Considerations
4 Hazards Identification
12 Transport Information
First Aid
RID/ADR- Non-hazardous for road transport.IMDG- Non-hazardous for sea transport.IATA - Non-hazardous for air transport.
As specific country, federal, state and local environmental
regulations vary and change frequently we suggest you contact a local, authorized waste disposal contractor for adequate disposal.
Special indication of hazards to humans and the environment.Irritating to eyes, respiratory system and skin.
MATERIALS TO AVOID- Strong oxidizing agents.
REACTIVITY- May emit toxic gasses like Carbon monoxide,Carbon dioxide, Nitrogen oxides upon thermal decomposition.
513 Other Information
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Medchemexpress LLC shall not be held liable for any damage resulting from h dli f t t ith th b d t
INHALATION- If inhaled, remove to fresh air. If not breathing give, artificial respiration. If breathing is difficult, give oxygen.SKIN CONTACT- In case of contact, immediately wash skin with soap and copious amounts of water.
EYE CONTACT- In case of contact, immediately flush eyes with copious amounts of water for at least 15 minutes.
INGESTION- If swallowed, wash out mouth with water provided person is conscious. Call a physician.
6 Fire Fighting Measures
handling or from contact with the above product.EXTINGUISHING MEDIA
Water spray- Carbon dioxide, dry chemical powder, or appropriate foam.SPECIAL RISKS
Specific Hazard(s)- Emits toxic fumes under fire conditions.SPECIAL PROTECTIVE EQUIPMENT FOR FIREFIGHTERS Wear self-contained breathing apparatus and protective clothing Caution: Not fully tested. For research purposes only
Medchemexpress LLC
to prevent contact with skin and eyes.
㪈㪏㪮㫀㫃㫂㫀㫅㫊㫆㫅㩷㪮㪸㫐㪃㩷㪧㫉㫀㫅㪺㪼㫋㫆㫅㪃㩷㪥㪡㩷㪇㪏㪌㪋㪇㪃㪬㪪㪘
㪜㫄㪸㫀㫃㪑㩷㫀㫅㪽㫆㪗㫄㪼㪻㪺㪿㪼㫄㪼㫏㫇㫉
㪼㫊㫊㪅㪺㫆㫄㩷㪮㪼㪹㪑㩷㫎㫎㫎㪅㫄㪼㪻㪺㪿㪼㫄㪼㫏㫇㫉㪼㫊㫊㪅㪺㫆㫄。